Evidence map›Paper›PMID 41428976›Full record

Trial reportJCO precision oncology2025

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (

Tejas Patil, Jessica J Lin, Parneet K Cheema, Daniel R Carrizosa, Mark E Burkard, Yasir Y Elamin, Jayesh Desai, Jyoti D Patel, Misako Nagasaka, Karen L Reckamp and 17 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Tejas PatilUniversity of Colorado Cancer Center, Aurora, CO.ORCID 0000-0003-4389-1010
Jessica J LinMassachusetts General Hospital, Boston, MA.ORCID 0000-0001-7373-3916
Parneet K CheemaWilliam Osler Health System, Calgary, Canada.
Daniel R CarrizosaLevine Cancer Institute/Atrium Health, Charlotte, NC.ORCID 0000-0003-1347-4232
Mark E BurkardUniversity of Iowa Health Care Holden Comprehensive Cancer Center, Iowa City, IA.ORCID 0000-0002-4215-7722
Yasir Y ElaminThe University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5312-909X
Jayesh DesaiPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID 0000-0003-4246-9344
Jyoti D PatelNorthwestern University, Chicago, IL.ORCID 0000-0002-7550-2094
Misako NagasakaChao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA.ORCID 0000-0001-5308-615X
Karen L ReckampCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-9213-0325
Saiama N WaqarWashington University School of Medicine, St Louis, MO.
Jessica R BaumanFox Chase Cancer Center, Philadelphia, PA.ORCID 0000-0001-8691-0387
Alison M SchramMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-6070-2413
Shirish M GadgeelHenry Ford Cancer Institute/Henry Ford Health System, Detroit, MI.ORCID 0000-0001-5240-3811
Patrick C MaPenn State Cancer Institute, Penn State University, Hershey, PA.ORCID 0000-0002-8425-1223
Kartik KonduriBaylor Charles A. Sammons Cancer Center, Texas Oncology PA, Dallas, TX.
Danny NguyenCity of Hope, Huntington Beach, CA.ORCID 0000-0002-2479-2271
Jamal MislehMedical Oncology Hematology Consultants, Newark, DE.ORCID 0009-0004-7747-0948
Jonathan BleekerSanford USD Medical Center, Sioux Falls, SD.ORCID 0000-0001-9003-7285
Matthias WeissThedaCare Cancer Center, Appleton, WI.ORCID 0000-0003-2744-0973
Subotheni ThavaneswaranThe Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, Australia.ORCID 0000-0002-8946-6709
Eric B HauraH. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Maegan DeeganElevation Oncology, Inc., Boston, MA.ORCID 0000-0003-1941-9795
Jonathan KaufmanElevation Oncology, Inc., Boston, MA.
Jaya SrivastavaElevation Oncology, Inc., Boston, MA.ORCID 0009-0001-6489-9014
Valerie M JansenElevation Oncology, Inc., Boston, MA.
Stephen V LiuLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.ORCID 0000-0002-4852-3914

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeNeuregulin-1 ( PATIENTS AND

methodsThis was a prospective phase II clinical study in which patients with advanced solid tumors harboring an

resultsA total of 54 patients with nine different tumor types featuring 19 different

conclusionThese results support the antitumor activity and safety of seribantumab in patients with advanced solid tumors harboring

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedNeoplasmsNeuregulin-1Receptor, ErbB-3AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedERBB3 protein, humanNeuregulin-1NRG1 protein, humanReceptor, ErbB-3seribantumab

Identifiers

PMID41428976
PMCPMC12736398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.